Hantavirus Treatment

There is currently no FDA-approved antiviral drug for hantavirus. Treatment is supportive β€” focused on managing symptoms and keeping organ systems functioning until the immune system clears the infection.

⚠️ Emergency β€” Act Immediately

Hantavirus Pulmonary Syndrome (HPS) can progress from mild flu-like symptoms to respiratory failure within hours. If you have fever, muscle aches, and recent rodent or confirmed patient contact, go to an emergency room immediately. Do not wait.

Supportive Care (Primary Treatment)

Supportive care is the cornerstone of hantavirus treatment and must be administered in an intensive care unit (ICU) by experienced clinicians.

Oxygen & Ventilation

Supplemental oxygen or mechanical ventilation for patients with respiratory failure.

Fluid Management

Careful IV fluid balance β€” too much fluid worsens pulmonary edema; too little causes shock.

ECMO

Extracorporeal membrane oxygenation (ECMO) used in the most severe HPS cases as a bridge to recovery.

Blood Pressure Support

Vasopressors (e.g. norepinephrine) to maintain blood pressure during cardiogenic shock.

Dialysis

Renal replacement therapy for HFRS patients with acute kidney injury.

Fever & Pain Management

Acetaminophen for fever and pain. Aspirin and NSAIDs should be avoided.

Ribavirin β€” Limited Evidence

Ribavirin (an antiviral) has shown benefit in reducing mortality for HFRS (Hemorrhagic Fever with Renal Syndrome) if given early. However, for HPS (the strain linked to the MV Hondius 2026 outbreak), clinical trials have not demonstrated significant benefit, and ribavirin is not routinely recommended for HPS.

Source: CDC Hantavirus Treatment Guidelines; NEJM 2022 Ribavirin Review.

HPS vs HFRS β€” Treatment Differences

FeatureHPS (Americas / Andes virus)HFRS (Europe / Asia)
Primary organLungsKidneys
ICU requiredAlmost alwaysSevere cases
Ribavirin benefitNot provenYes (early treatment)
ECMO useYes, in critical casesRarely needed
Mortality (untreated)30–50%1–15%

Prognosis & Recovery

Patients who survive the critical phase (first 5–7 days of severe disease) typically recover completely. Most survivors report full pulmonary function within 6 months. Long-term complications are uncommon but may include fatigue, exercise intolerance, and in HFRS β€” chronic kidney impairment.

The MV Hondius 2026 outbreak (Andes virus) has a case fatality rate of approximately 38% β€” significantly higher than historical HPS averages β€” possibly due to delayed diagnosis and person-to-person transmission in a confined environment.

Related Pages

Last reviewed: May 10, 2026. This page is for informational purposes only. Consult a physician for medical advice. Medical Disclaimer